RT @paomorejon: 📌ACO y sobrevida🏥 #COVID19 🦠 📉☠️👥ventilados 34% (29.1% vs 62.7%) La curva luce 👍🏻 ☠️🏥22.5% vs 22.8% Mediana: 21 días vs 1…
RT @paomorejon: 📌ACO y sobrevida🏥 #COVID19 🦠 📉☠️👥ventilados 34% (29.1% vs 62.7%) La curva luce 👍🏻 ☠️🏥22.5% vs 22.8% Mediana: 21 días vs 1…
RT @jungleland: So sad. A person who has COVID19 doesn’t need you to give them a brain bleed on top of it. #evidencebasedmedicine
Just heard from a physician at Cleveland Clinic earlier this week that "every hospitalized Covid patient needs to be started on prophylactic Lovenox". Reminds me of a discussion earlier about dealing with misinformation—a hard problem when experts are advo
Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 #MicroCLOTS #Covid19 https://t.co/9kpuoFpqAE
📌ACO y sobrevida🏥 #COVID19 🦠 📉☠️👥ventilados 34% (29.1% vs 62.7%) La curva luce 👍🏻 ☠️🏥22.5% vs 22.8% Mediana: 21 días vs 14 🩸3% vs 1.9% 🤚🏻🚫🤔 Reduce la mortalidad o sobreviven 7 días más⁉️ La RAR del 34% en👥críticos⁉️ Generador de hipótesis https://t.co
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @DanielJafari: Anticoagulation serves a purpose. It prevents clot formation. In a portion of patients, this will lead to catastrophic bl…
RT @j_alvarezgarcia: 📣El uso de anticoagulación pdría relacionarse con mejor pronóstico en pacientes hospitalizados por #COVID19 👉Importan…
RT @iamritu: @adamcifu It’s all in the narrative, Adam @adamcifu @djc795 https://t.co/N34DzpzH14
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Tons of value in the comment/discussion
RT @edurontoFF: .Valentin Fuster #JACC. 2,773 p. #COVID19, 395 en ARM, en ellos: Mortalidad hospitalaria 29.1% anticoagulados vs 62.7% en p…
RT @GBarnesMD: Ido - I agree, the paper does not answer the question "how best to prevent #thrombosis in #COVID19?" However, it does provid…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Anticoagulation serves a purpose. It prevents clot formation. In a portion of patients, this will lead to catastrophic bleeds. Every single study of AC for other indications says so.
Pacient s preventivní koagulací při Covid19. Asi to nebude ideální volba.
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @AAlMohammad87: RCT of Anticoagulation/ACEi, may well hold some answers to the catastrophic consequences of #COVID19, even if they are n…
RT @GBarnesMD: Ido - I agree, the paper does not answer the question "how best to prevent #thrombosis in #COVID19?" However, it does provid…
RT @Angiologist: Does this paper answer the question of FULL DOSE anticoagulation in #COVID19? I don't think so @JACCJournals... e.g. limi…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @Dr_Cit: Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 https://t.co/…
RT @edurontoFF: .Valentin Fuster #JACC. 2,773 p. #COVID19, 395 en ARM, en ellos: Mortalidad hospitalaria 29.1% anticoagulados vs 62.7% en p…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @JACCJournals: New research published in #JACC from Journal Editor-in-Chief Dr. Valentin Fuster and team @IcahnMountSinai finds #cvCoag…
RT @iamritu: Observational study of n=786 w possible unobserved confounding, unknown indication for AC, lack of metrics to further classify…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @Dr_Cit: Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19 https://t.co/…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Potential survival advantage for #COVID19 patients treated with anticoagulation (preprint @JACCJournals) particularly for patients requiring mechanical ventilation. https://t.co/RQBhLWaqWS https://t.co/fzBQzrY3oY
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
new research letter in JACC describing a retrospective analysis of full-dose anticoagulation in COVID pts. overall, patients who lived longer tended to live longer. in short, RCT results are needed before a strategy like this is adopted https://t.co/NK3S8
RT @JACCJournals: New research published in #JACC from Journal Editor-in-Chief Dr. Valentin Fuster and team @IcahnMountSinai finds #cvCoag…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @JACCJournals: New research published in #JACC from Journal Editor-in-Chief Dr. Valentin Fuster and team @IcahnMountSinai finds #cvCoag…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Ups!
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @JACCJournals: New research published in #JACC from Journal Editor-in-Chief Dr. Valentin Fuster and team @IcahnMountSinai finds #cvCoag…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
@daniyal_asim
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @ChooseWiselyBR: Immortal Time Bias in Pharmacoepidemiology: https://t.co/eawkKwLrPA
Association of Treatment Dose Anticoagulation with In-Hospital Surviva... https://t.co/z4DfXjK0qz
Immortal Time Bias in Pharmacoepidemiology: https://t.co/eawkKwLrPA
RT @ProfMakris: Short report (too short) of an observational study suggests that fully anticoagulated patients do better in terms of surviv…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @nickmmark: Observational study of n=786 #COVID pt who received treatment dose #anticoagulation (AC) vs n=1987 who did not. AC associate…
RT @RichardAFerraro: Really good discussion on pitfalls and limitations of observational studies.
@GilbertDeray biais d’immortalité, bien expliqué par @FZores https://t.co/Ti9h9YKwFP
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @iamritu: Observational study of n=786 w possible unobserved confounding, unknown indication for AC, lack of metrics to further classify…
Check out this article from a multi-disciplinary @mountsinainyc team including #MountSinaiAnesthesia highlighting the data that drove our approach to more aggressive anticoagulation of COVID patients https://t.co/S5siVjPfwu https://t.co/xwk0P2Rjb8
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Se debe utilizar la ciencia para beneficio de los pacientes. La anticoagulación tiene beneficios probados en pacientes con trombosis venosa profunda y otras enfermedades, el riesgo es el sangrado, justificado en el balance riesgo/beneficio a favor. Pero ju
RT @j_alvarezgarcia: 📣El uso de anticoagulación pdría relacionarse con mejor pronóstico en pacientes hospitalizados por #COVID19 👉Importan…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Fascinating new study from my alma mater re: anticoag in COVID...wish we could fast fwd 10 yrs to look back on all this emerging evidence with the wisdom of hindsight.
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @mirvatalasnag: Important🧵 #OAC #COVID19 🔸Routine use of OAC @ study center, so control arm were those w contraindication (observational…
RT @IanMedical: La otra cara de lo observación al https://t.co/q6JgVISrDh
RT @IHaznedaroglu: @ShirleyManson84 @lsmtnhl @SehsuvarErturk Bizde ölümlerin daha az görülmesi bu ilaç kombinasyonundan değil; erkenden LMW…
@DrDerekConnolly @DrAsifQasim @SABOURETCardio I couldn't wrap my head around some of the statistics in this study. Found some good threads explaining the confounders in thr study, esp immortal time bias: https://t.co/yyIZTFarEY
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Really good discussion on pitfalls and limitations of observational studies.
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
La otra cara de lo observación al
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
Important observation of the potential association/impact of full dose anticoagulation on #COVID19 @JACCJournals https://t.co/tlsOqHDHiJ It is important to consider an RCT on formal AC in all patients with #COVID19
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…
RT @drjohnm: PSA for COVID19 Rx Don’t use flawed observational data to start giving potent anticoagulation to sick pts with COVID19. Even…